Navigation Links
Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/19/2008

PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced that it has cancelled its corporate presentation planned for today at the Lazard Capital Markets 5th Annual Healthcare Conference due to the proximity of the release of preliminary top-line data from the first Phase III pivotal clinical trial of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

The company anticipates that it will release the preliminary top-line data within the next week.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains a forward-looking statement related to the timing of the release of clinical results related to Jazz Pharmaceuticals' JZP-6 product candidate for the treatment of fibromyalgia. This forward-looking statement is based on the company's current expectations and inherently involves significant risks and uncertainties. The actual timing of the release of clinical results could differ from that anticipated in such forward-looking statement as a result of these risks and uncertainties. Risk factors related to Jazz Pharmaceuticals' clinical trials are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 14, 2008.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MiddleBrook Pharmaceuticals Hires Key Commercial Team Members
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... to a new market research report "In situ Hybridization Market by Technique (FISH, ... Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by MarketsandMarkets, ... 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... Logo ...
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project ... fight to end Duchenne muscular dystrophy (Duchenne) , ... the New Jersey Institute of Technology (NJIT) and Talem ... exploration of robotic technology to assist people living ... incorporate NJIT,s technology – an embedded computer, software, a ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated ... year and is planned for further growth in 2017. Extractable & Leachable evaluations ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... not fall low enough after prostate cancer treatment, this indicates there is still remaining prostate ... of mortality. , “ The PSA test has always been an indicator of whether a ...
Breaking Biology Technology:
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... ... announced the addition of the "Global Military Biometrics Market 2016-2020" ... military biometrics market to grow at a CAGR of 7.5% during the ... an in-depth market analysis with inputs from industry experts. The report covers ... report also includes a discussion of the key vendors operating in this ...
Breaking Biology News(10 mins):